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1. Introduction
Metastatic melanoma is the most aggres-
sive form of skin cancer, and patients 
with the disease continue to have a poor 
prognosis after treatment.[1–3] Metastatic 
melanoma develops through the dissemi-
nation of melanoma cells from the pri-
mary tumor site to different parts of the 
body (e.g., lung, liver, spleen, and kidney) 
via the circulatory and lymphatic sys-
tems.[4,5] In clinical practice, there are sev-
eral options for the treatment of metastatic 
melanoma, including immunotherapy, 
radiation therapy, and chemotherapy.[3] 
In melanoma, the serine/threonine pro-
tein kinase BRAF plays a critical role 
in growth signaling transduction in the 
mitogen-activated protein kinase (MAPK) 
pathway.[6–8] Over 90% of tumorigenic 
BRAF mutations appear at codon 600 
(V600E), where an α-amino acid (valine; 
V) position in the protein kinase domain 
is substituted by glutamic acid (E).[9,10] 
Kinase activity in melanomas harboring 
Metastatic melanoma can be difficult to detect until at the advanced state that 
decreases the survival rate of patients. Several FDA-approved BRAF inhibitors 
have been used for treatment of metastatic melanoma, but overall therapeutic 
efficacy has been limited. Lutetium-177 (177Lu) enables simultaneous tracking of 
tracer accumulation with single-photon emission computed tomography and 
radiotherapy. Therefore, the codelivery of 177Lu alongside chemotherapeutic 
agents using nanoparticles (NPs) might improve the therapeutic outcome 
in metastatic melanoma. Cellulose nanocrystals (CNC NPs) can particularly 
deliver payloads to lung capillaries in vivo. Herein, 177Lu-labeled CNC NPs 
loaded with vemurafenib ([177Lu]Lu-CNC-V NPs) is developed and the thera-
peutic effect in BRAF V600E mutation-harboring YUMM1.G1 murine model of 
lung metastatic melanoma is investigated. The [177Lu]Lu-CNC-V NPs demon-
strate favorable radiolabel stability, drug release profile, cellular uptake, and cell 
growth inhibition in vitro. In vivo biodistribution reveals significant retention of 
the [177Lu]Lu-CNC-V NPs in the lung, liver, and spleen. Ultimately, the median 
survival time of animals is doubly increased after treatment with [177Lu]Lu-
CNC-V NPs compared to control groups. The enhanced therapeutic efficacy of 
[177Lu]Lu-CNC-V NPs in the lung metastatic melanoma animal model provides 
convincing evidence for the potential of clinical translation for theranostic CNC 
NP-based drug delivery systems after intravenous administration.
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the BRAF V600E mutation is elevated 500- to 700-fold com-
pared to wild-type BRAF, leading to cell transformation and 
tumor formation.[11] In addition, the BRAF V600E mutation is 
found in 40–60% of melanoma patients, rendering it a prom-
ising candidate for targeted therapy.[12] PLX4032 (vemurafenib) 
is a clinically approved tyrosine kinase inhibitor that inhibits 
ATP binding in BRAF V600E-mutated melanomas, resulting 
in the deactivation of the MAPK pathway and reduction in cell 
proliferation and survival.[13,14] However, the therapeutic efficacy 
of vemurafenib remains suboptimal due to the need for high 
doses, poor bioavailability of the drug, adaptive drug resistance 
behavior, and the reactivation of the MAPK pathway from drug-
induced stress responses after repeated cycles of treatment.[14–17]
Radiolabeled tracers have been applied in oncology for diag-
nosis, staging, therapy, and long-term monitoring of numerous 
cancers.[18] Lutetium-177 (177Lu) is a theranostic radionu-
clide that is frequently used in the clinic due to physical and 
nuclear properties—a relatively long half-life (t1/2 = 6.6 d) and 
the emission of both gamma (γ) and beta (β−) radiation—that 
enable simultaneous imaging and radiotherapy. The emission 
of gamma radiation (Eγ  = 208  keV, 10% intensity) facilitates 
noninvasive diagnostic imaging using single-photon emission 
computed tomography (SPECT). The β− radiation (Eβmax  = 
0.498 MeV, 79% intensity) enables endoradiotherapy through 
the deposition of ionizing particles that induce cytotoxic ROS 
formation and DNA double-strand breaks within the cells.[19,20]
Nanostructured materials have been employed in the field 
of nanomedicine as drug delivery systems (DDS) intended to 
address the limitations in conventional formulations.[21,22] Nano-
particles (NPs) are a versatile platform that can be tailored to 
have the desired characteristics and properties for specific 
drug delivery applications. Engineered NPs offer several advan-
tages, including improved drug solubility, controlled drug 
release, increased drug circulation half-life, and enhanced 
targetability.[23–25] Cellulose is an abundant biomacromolecular 
material obtained from various renewable resources.[26,27] In 
drug delivery applications, nanocrystalline cellulose nanopar-
ticles (CNC NPs) have received great interest as a biopolymer-
based nanomaterial that can be easily and economically prepared 
from the separation of the crystalline regions of native cellulose 
through strong acid hydrolysis.[28,29] The CNC NPs possess ver-
satile physical and chemical properties, including a needle-like 
structure with dimensions of 5–10 nm in width and 100–300 nm 
in length (for CNC NPs derived from wood and cotton), a high 
aspect ratio (length/width), and surface chemistry that is ame-
nable to conjugation via the manipulation of hydroxyl (OH), 
aldehyde (CHO), and sulfate (OSO3) groups.[29,30] Furthermore, 
the biocompatibility, biodegradability, and lack of toxicity of CNC 
NPs has led many to advocate their use in biomedical applica-
tions.[31–35] According to our previous reports,[31,35] radiolabeled 
CNC nanoparticles display a transient uptake and retention in 
the lung tissue, suggesting that rod-shaped CNC NPs could be 
used to target the pulmonary vasculature as they tumble close 
to the wall of the blood vessels and could potentially embolize 
into neovascularization of the metastatic tumors.[36] Since CNC 
NPs tend to accumulate in the lung vasculature, the delivery of 
vemurafenib with CNC NPs to metastatic melanoma in the lung 
is an attractive model to explore the drug delivery potential of 
the CNC NPs to lung tissue. Furthermore, the CNC NPs can 
be readily radiolabeled with the theranostic radioisotope 177Lu to 
explore the potential synergistic or added effects of 177Lu-radio-
therapy and vemurafenib chemotherapy.
In this study, we developed theranostic 177Lu-labeled CNC 
NPs loaded with vemurafenib ([177Lu]Lu-CNC-V NPs, Figure 1) 
and investigated their biological behavior in both murine and 
human melanoma cell models and animals bearing metastatic 
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Figure 1. Schematic representation of the 177Lu-labeled CNC NPs loaded with vemurafenib ([177Lu]Lu-CNC-V NPs). The green rod represents a cotton 
cellulose nanocrystal (CNC NP). The bifunctional radiometal chelator DOTA-NH2 is conjugated on the CNC surface via CDI-activated OH groups and 
further radiolabeled with 177Lu. Vemurafenib is entrapped on the surface of CNC by electrostatic interaction with the aid of poly-L-lysine as a capping agent.
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melanoma allografts in the lung. The theranostic CNC NPs were 
prepared through the conjugation of 1,4,7,10-tetraazacyclodode-
cane-1,4,7,10-tetraacetic acid (DOTA) to the hydroxyl groups on 
the surface of the CNC NPs followed by radiolabeling with 177Lu. 
Then, vemurafenib was incorporated onto the surface of the 
177Lu-labeled CNC NPs via the electrostatic interactions using a 
cationic polymer (poly-l-lysine) as a capping agent. The in vitro 
radiolabeling stability and drug release profiles of the [177Lu]Lu-
CNC-V NPs were studied in different physiological simulated 
conditions. Furthermore, the cell cytotoxicity, cellular uptake, 
and clonogenic cell survival were evaluated in both murine and 
human melanoma cell models. Finally, the ex vivo biodistribu-
tion and therapeutic studies of the [177Lu]Lu-CNC-V NPs were 
assessed in mice bearing YUMM1.G1 lung metastatic mela-
noma allografts for preclinical evaluation of the theranostic CNC 
NP-based DDS and its potential of future clinical translation.
2. Results and Discussion
2.1. Materials Characterization
The DOTA-modified CNC NPs were successfully prepared 
through the CDI-mediated amidation reaction between the 
activated hydroxyl groups and DOTA-NH2. When compared 
to unmodified CNC spectrum, the ATR-FTIR spectrum of the 
DOTA-CNC NPs contained the conjugation product peaks, 
including the amide II band (CN stretching and NH 
bending) at 1510–1700 cm−1, and alkyl band (CH stretching) 
at 2850–2950 cm−1, demonstrating successful conjugation of 
DOTA chelator to the surface of the CNC NPs (Figure S1, Sup-
porting Information). Moreover, the changes in the C, H, and 
N compositions of modified CNC NPs corroborated the suc-
cessful conjugation reaction. While there was no significant dif-
ference in the C and H content from that of unmodified CNC 
NPs, the amount of N increased substantially to approximately 
0.9% in the DOTA-CNC NPs, presumably due to the presence 
of the N in the DOTA macrocyclic ring (Table S1, Supporting 
Information). The N content was further used to estimate the 
degree of substitution (DS), providing the average number of 
DOTA molecules attached per monomeric unit of the CNC NPs 
(Supporting Information). The DS of DOTA molecules to the 
CNC NPs was approximately 0.24, which is in agreement with 
the values reported in the literature where the DS of grafting 
molecules on the cellulose surface through heterogeneous 
reactions is generally less than 1.0 as a result of an unreactive 
hydroxyl group at the carbon position C2 and C3 of the anhy-
droglucose unit.[37] The DOTA-CNC NPs showed an increase 
in zeta (ζ)-potential value (−30.67 ± 0.91 mV) compared to the 
native CNC NPs (−52.53 ± 2.67 mV). However, the negative sur-
face charge of the DOTA-modified CNC NPs is sufficiently low 
to avoid nonspecific adsorption of plasma proteins.[38] Upon 
capping with PLL, the ζ-potential reversed to positive (47.23  ± 
1.26  mV) and was lowered to close to 0  mV (1.72  ± 0.27  mV) 
in the full 177Lu-radiolabeled [177Lu]Lu-CNC-PLL-V nanothera-
nostic construct. Compared to neutral or negatively charged 
nanoparticles, positively charged nanoparticles have a stronger 
interaction with the negatively charged cell membrane driven 
by electrostatic attraction. The slightly positive charge of [177Lu]
Lu-CNC-PLL-V NPs might favor the cell adhesion both in vitro 
and in vivo, leading to higher accumulation within cells.[39] 
The ζ-potential results of all nonradiolabeled and radiolabeled 
CNC NPs in this work are compiled in Table S2, Supporting 
Information. In addition, FE-SEM images were acquired to 
determine the morphology of the CNC NPs after the chemical 
modifications. There is no dramatic change in the morphology 
of the modified CNC NPs compared to unmodified CNC NPs, 
and all the CNC NPs demonstrated a rod-like shape with an 
average width of 9–14 nm and length of 136–158 nm as well as a 
uniform particle size distribution (Figure 2 and Figure S2, Sup-
porting Information).
2.2. 177Lu-Radiolabeled CNC NPs and In Vitro Stability
The DOTA-CNC NPs were successfully labeled with 177Lu using 
standard radiolabeling procedures with a decay-corrected radi-
ochemical yield (RCY = 74  ± 2%, n  = 4) and a radiochemical 
purity (RCP >  99.5%) after purification. The in vitro stability 
of 177Lu-radiolabeled CNC construct was thoroughly studied in 
various simulated physiological conditions, including 1× PBS 
(pH 7.4), and 50% and 100% human plasma. The stability of the 
radiometal–ligand complex was also investigated using 0.2  × 
10−3 m FeCl3 and 2 × 10−3 m EDTA as a competing metal and 
ligand, respectively.
In general, the [177Lu]Lu-CNC NPs demonstrated good radi-
olabel stability with >99.5% of the 177Lu radiolabel remaining 
bound to the surface of the CNC NPs after 96 h of incubation 
in 1× PBS (pH 7.4), and in 50% and 100% human plasma in 
1× PBS (pH 7.4) at 37 °C (Figure 3A). The results suggest that 
plasma proteins have no significant effect on the radiolabel 
complex stability or nanomaterial degradation, indicating 
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suitability for in vivo use. Moreover, the [177Lu]Lu-CNC NPs 
revealed remarkable complex stability (≥99.5% intact) over 96 h 
of incubation in 0.2  × 10−3 m FeCl3 solution where the Fe3+ 
concentration was considerably higher than the normal range 
(10–30 × 10−6 m) in human tissues.[40] Similarly, the percentage 
of intact [177Lu]Lu-DOTA-CNC NPs in 2 × 10−3 m EDTA solution 
was maintained at 99.8% over the incubation period, which 
indicates stable coordination of the [177Lu]Lu3+ in the DOTA 
chelator (Figure 3B).
2.3. Drug-Loaded CNC NPs and In Vitro Drug Release Profiles
Vemurafenib was successfully loaded to both nonradiolabeled 
and radiolabeled CNC NPs through noncovalent binding on the 
surface of the CNC in the presence of cationic PLL as a cap-
ping agent, promoting the electrostatic binding of the hydro-
phobic drug. The nonradiolabeled PLL-CNC-V NPs showed a 
moderate drug loading efficiency of 13.13  ± 1.00%, while the 
loading efficiency on the radiolabeled [177Lu]Lu-CNC-V NPs 
(29.50  ± 3.50%) was improved about twofold (Table S3, Sup-
porting Information). This might be the result of a higher 
positive surface charge of [177Lu]Lu-CNC NPs compared to non-
radiolabeled CNC NPs (Table S2, Supporting Information). The 
additional negative charge from the deprotonated carboxylic 
acid residues on the DOTA chelator of [177Lu]Lu-CNC-V NPs 
could promote the capping with PLL, which may drive a greater 
amount of vemurafenib to entrap on the surface of the CNC 
in radiolabeled particles. Moreover, the obtained drug loading 
efficiency and loading degree of nonradiolabeled CNC NPs in 
this work were slightly lower than those reported for the CNC 
NP-based DDS in the literature, in which the average loading 
efficiency and loading degree for hydrophobic compounds have 
ranged between 21–25% and 14–20%, respectively.[41–43]
The ability of the developed CNC NPs DDS to release the 
vemurafenib payload was first evaluated in physiological fluids 
in vitro, including 1× PBS (pH 7.4) and 10  × 10−3 m acetate 
buffer (pH 5.5) for blood and tumor microenvironment mim-
icking conditions, respectively. Overall, both PLL-CNC-V NPs 
and the [177Lu]Lu-CNC-V NPs exhibited a rapid release pattern 
of vemurafenib after 2 h of incubation in both simulated media 
before the release kinetics were sustained over the incubation 
period (Figure 4). Interestingly, both NP constructs demon-
strated superior drug release rate in 1× PBS (pH 7.4) in which 
the cumulative release reached 80% and 66% while only 64% 
and 47% were attained at pH 5.5 after 96 h of incubation for 
PLL-CNC-V NPs and [177Lu]Lu-CNC-V NPs, respectively. This 
phenomenon could be explained by the fact that the PLL coated 
on the surface of CNC is bound by electrostatic interactions. 
A strong electrolyte of 137 × 10−3 m NaCl in PBS buffer might 
screen some electrostatic interactions and weaken the binding 
of PLL, resulting in loss of the capping capacity. Furthermore, 
the 10% (v/v) human serum added to the incubation media in 
order to induce a sink condition could promote the scavenging 
of the PLL coating due to electrostatic interactions with the 
serum proteins.
Figure 3. The in vitro stability of 177Lu-radiolabeled CNC NPs in A) 1× PBS (pH 7.4), and in 50% and 100% human plasma in 1× PBS (pH 7.4), and 
B) 0.2 × 10−3 m FeCl3 and 2 × 10−3 m EDTA challenges. The values represent mean ± s.d. (n = 3).
Figure 4. In vitro drug release profiles of A) vemurafenib-loaded nonradiolabeled PLL-CNC-V NPs and B) vemurafenib-loaded radiolabeled [177Lu]
Lu-CNC-V NPs in simulated physiological 1× PBS (pH 7.4) and condition mimicking the tumor microenvironment (pH 5.5, representing the late endo-
some) over 96 h. The values represent mean ± s.d. (n = 3).
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In contrast, the release profiles of the [177Lu]Lu-CNC-V NPs 
in both conditions were decelerated compared to the nonra-
dioactive PLL-CNC-V NPs. This might be the influence from 
the carboxylic residues on the nonradiolabeled DOTA chelator 
left on the surface of the [177Lu]Lu-CNC-V NPs after radiola-
beling. The negative charge from the carboxylic groups might 
foster an interaction with vemurafenib while PLL starts to lose 
its capping capacity, leading to a slower drug release pattern. 
Therefore, the drug loading strategy and coating materials for 
surface stabilization could be further optimized to enhance the 
capping capacity and minimize the release at physiological pH 
7.4 while triggering a burst release at the acidic pH of the tumor 
microenvironment. Regardless of the room for improvement, 
the results demonstrate that both non-radiolabeled and radiola-
beled CNC NPs are promising nanocarriers for the delivery of 
vemurafenib with satisfactory release behavior for in vivo use.
2.4. In Vitro Cytocompatibility
Despite the promising radiolabeling yield, radiolabel stability 
and drug release pattern of the CNC NPs, the cytotoxicity of the 
newly developed vemurafenib-loaded CNC NPs is an important 
issue that needs to be investigated before in vivo applications. 
The in vitro cytotoxicity screening test could provide pre-
liminary information on the potential toxicity and subcellular 
targeting of drug-loaded nanoparticles that could suggest a pre-
diction of in vivo effects. The in vitro cytotoxicity of the PLL-
CNC-V NPs was studied in both BRAF V600E mutant cell lines 
(murine YUMM1.G1 and human A375) and wild-type BRAF 
cell line (murine B16-F10) at various concentrations and incu-
bation times. In general, the YUMM1.G1 and A375 cell lines 
exhibited a linear decrease in cell viability when incubated with 
either free vemurafenib or PLL-CNC-V NPs at increasing con-
centrations over time (Figure 5). The PLL-CNC-V NPs were less 
cytotoxic than free vemurafenib in both cell lines up to 24  h 
of incubation, suggesting the capability of CNC NPs to sus-
tain the release of vemurafenib over time before the cytotoxic 
effect became similar at 48 h and 72 h of incubation (Table S4, 
Supporting Information). Moreover, the downstream effects of 
BRAF inhibition in YUMM1.G1 and A375 cell lines were cor-
roborated with western blot showing that MEK phosphorylation 
was successfully inhibited with the increase in vemurafenib 
concentration (Figure S3, Supporting Information) in both of 
the cell lines. As expected, the PLL-CNC NPs (empty nano-
system) showed no significant cytotoxic effect at any of the con-
centrations up to 48 h of incubation, which was in accordance 
with our previous reports.[31,32] However, a slight decrease in cell 
Figure 5. In vitro cell viability studies in BRAF V600E expressing cell lines (human A375 and murine YUMM1.G1 melanoma) and wild-type BRAF 
expressing melanoma cell line (murine B16-F10) after incubation with free vemurafenib, PLL-CNC NPs, and PLL-CNC V NPs at vemurafenib concentra-
tions of 0.1 × 10−6, 0.5 × 10−6, 1.0 × 10−6, and 1.5 × 10−6 m with respective CNC concentrations of 0.5, 2.2, 4.5, and 6.7 µg mL−1 for 6, 24, 48, and 72 h. 
For B16-F10 the assay was carried out only at 24 and 72 h. The negative (−) and positive (+) controls for cell viability were fresh cell culture media and 
1% (v/v) Triton X-100 solution, respectively. The statistical analysis was carried out using the unpaired Student’s t-test in comparison with the negative 
control where the significant differences were set at *p < 0.05, ** p < 0.01, and ***p < 0.001. Columns represent the mean ± s.d. (n = 4).
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viability (<90%) was observed at 4.5 and 6.7 µg mL−1 concentra-
tions after 72 h of incubation in both cell lines. This might be 
due to the potential cytotoxicity induced by the cationic charge 
of PLL after long exposure time with the cells. Additionally, 
in order to further corroborate that the cytotoxic effects were 
primarily arising from the vemurafenib release and effects in 
the BRAF V600E mutant cell lines, the cytotoxicity of the con-
structs was assayed in the murine BRAF wild-type B16-F10 mel-
anoma cell line at 24 and 72 h representing medium and long 
exposure times. The proportion of viable B16-F10 cells stayed 
over 90% for all conditions, concentrations and time points. 
Therefore, the overall results indicate the potential to use of the 
CNC NPs as a nanocarrier to delivery and sustained release of 
vemurafenib to tumor cells expressing the BRAF V600E muta-
tion in vivo, while the construct remains safe for nontarget cells 
expressing wild-type BRAF.
2.5. Cellular Uptake Studies
The internalization of NPs into the cells is often needed for 
successful transportation and accumulation of active molecules 
(e.g., drugs, DNA, RNA, and imaging agents) to specific intra-
cellular sites. The cellular uptake of nontargeted NPs is usually 
through the endocytosis pathway and penetration at the lipid 
bilayer on the cell membrane, however, other internalization 
pathways can be regulated for targeted NPs, such as ion chan-
nels, receptors, and transporters.[44] The uptake mechanisms of 
NPs vary depending on size, uniformity of the size distribution, 
shape, and surface properties. Typically, the internalization 
in cells is qualitatively determined through the visualization 
of the signal from a fluorescent dye tagged on the surface of 
NPs using fluorescence microscopy. However, the internaliza-
tion of the 177Lu-radiolabeled CNC constructs in this work is 
conveniently evaluated through the quantitative detection of 
gamma radiation from the 177Lu accumulated within the cells. 
The results showed that there was no substantial accumula-
tion of free [177Lu]Lu3+ in either YUMM1.G1 or A375 cell lines 
while an increase in internalized radioactivity within the cells 
was observed with the [177Lu]Lu-CNC NPs and [177Lu]Lu-CNC-V 
NPs over time (Figure 6). Both radiolabeled CNC NPs revealed 
a linear trend of radioactivity accumulation in both cell lines 
up to 24 h of incubation. Furthermore, [177Lu]Lu-CNC-V NPs 
exhibited a higher uptake in both cell lines compared to the 
[177Lu]Lu-CNC NPs with double the internalization at all time 
points. A greater degree of internalization of the [177Lu]Lu-CNC-
V NPs could be a result of the positive surface charge of the 
NPs (Table S2, Supporting Information), which possibly stimu-
lates a strong interaction with the negatively charged cell mem-
brane. Surprisingly, both the CNC NPs tend to accumulate in 
human A375 melanoma cells with approximately three times 
higher uptake than in murine YUMM1.G1 melanoma cells at 
all time points. Unlike spherical NPs, the interaction and inter-
nalization mechanisms of rod-shaped NPs, especially the CNC 
NPs in this work are not completely elucidated and could rely 
on different factors, including physicochemical properties of 
the NPs, the cell type, membrane-wrapping energy consump-
tion, activity of endocytosis pathways, and uptake behavior.[45] 
Moreover, the decrease of internalization after 48 h of incuba-
tion was noticed in both the radiolabeled CNC NPs in both 
tested cell lines. This is likely a result of the cytotoxic effect 
after long exposure during which the dead cells start to detach 
from the surface of the culturing plate. The detached cells with 
their accumulated radioactivity are potentially washed out to 
the unbound fraction, complicating the determination of the 
internalized activity at time points beyond 24 h.
2.6. Clonogenic Cell Survival
Clonogenic assays are commonly used to investigate the ability 
of cells to proliferate after exposure to ionizing radiation that 
induces DNA damage and cell apoptosis, but it is also useful 
for investigation of the combination of radiation with other 
treatment modalities.[46] In this experiment, the clonogenic cell 
survival in YUMM1.G1 and A375 cells was explored after treat-
ments with PLL-CNC NPs, free vemurafenib, free [177Lu]Lu3+, 
[177Lu]Lu-CNC NPs, and [177Lu]Lu-CNC-V NPs for 6, 24, and 
48 h to examine the effects of the chemoradiotherapeutic com-
bination of the [177Lu]Lu-CNC-V NPs and the individual nan-
otheranostic components (Figure 7). As the colonies formed by 
both cell lines tended to clump together, the plating efficiency 
and surviving fraction could not be accurately determined. 
Therefore, the discussion of results herein is simplified as a 
Figure 6. Cellular uptake of radioactivity after incubation with free A) [177Lu]Lu3+, [177Lu]Lu-CNC NPs, and [177Lu]Lu-CNC-V NPs in B) murine YUMM1.
G1 and human A375 melanoma cell lines at 1, 6, 24, and 48 h of incubation with fixed concentrations of 1 MBq mL−1 for 177Lu, 40 µg mL−1 for CNC NPs 
and 0.1 × 10−6 m for vemurafenib. The statistic was analyzed using the unpaired Student’s t-test between [177Lu]Lu-CNC NPs and [177Lu]Lu-CNC-V NPs 
at the same incubation time point where the significant probabilities were set at n.s. (not significant, p > 0.05), *p < 0.05, **p < 0.01, and ***p < 0.001. 
Columns represent the mean ± s.d. (n = 3).
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qualitative analysis through the overall intensity of the crystal 
violet staining in the samples. The theranostic [177Lu]Lu-CNC-V 
NPs revealed to be the most effective formulation, and there 
were no cell colonies formed after 24 and 48 h treatments in 
both cell lines. There was no clear difference in the stained cell 
colonies between samples treated with non-radioactive com-
ponents (vemurafenib and PLL-CNC NPs) alone compared 
to the negative control in all tested cell lines and time points. 
Undoubtedly, the PLL-CNC NPs are nontoxic and should not 
cause cytotoxicity, while in contrast vemurafenib at 0.1 × 10−6 m 
should already exhibit cytotoxic effects after 24 h incubation, 
as shown by the CellTiter-Glo assay results earlier. The lack 
of cytotoxic effects observed in the clonogenic assay for these 
components could be a result of drug resistance behavior in 
which different complex mechanisms, such as the efflux of 
anticancer drugs, the escape from therapy-induced senescence, 
and the enhanced DNA damage repair are elicited in response 
to treatment. This phenomenon only becomes apparent in the 
clones grown for the relatively long period of 10 d as opposed 
to the three day time frame of the cell viability assay.[47] The 
murine YUMM1.G1 cell line appears to be more radiosensitive 
than the human A375 cell line by comparison of the intensity 
of the crystal violet staining; however, the mechanisms under-
lying the differences in intrinsic radiosensitivity of cancer cell 
lines are variable and still under investigation.[48] Neverthe-
less, our results indicate that there is potential added thera-
peutic efficacy in the combination of BRAF inhibition with 
vemurafenib and 177Lu radiotherapy delivered in a single CNC 
NP platform in BRAF V600E-mutated melanoma, but with 
the limitations in the present clonogenic assay the molecular 
mechanism needs to be investigated in more detail in future 
studies. Furthermore, our results on the potential added effi-
cacy of the chemoradiotherapeutic combination are in line with 
those reported by Dasgupta and co-workers[49] in vitro with the 
combination of PLX4720 (another BRAF V600E targeting inhib-
itor) and external beam radiotherapy (EBRT). In that case, the 
potential mechanism underlying the added effects could be the 
suppression of ionizing radiation-induced MEK/ERK pathway 
activation by BRAF inhibition.[50,51] However, without a doubt 
the whole picture is more complex and the potential added or 
synergistic effects of BRAF inhibition and targeted radiotherapy 
will depend on the relative timing and doses of the two treat-
ment modalities.[52,53]
2.7. Ex Vivo Biodistribution and Dosimetry
The ex vivo biodistribution of the [177Lu]Lu-CNC-V NPs was first 
evaluated in YUMM1.G1 lung metastatic melanoma bearing 
C57BL/6NRj female mice prior to the therapeutic studies as the 
first step to examine the distribution profiles of the developed 
theranostic CNC NPs in vivo as a function of time. The YUMM1.
G1 cell is a congenic mouse melanoma cell line with C57BL/6J 
strain background and with defined genotype of BrafV600E/wt  
Pten−/− Cdkn2−/− Mc1re/e developed in the Yale University Mouse 
Melanoma (YUMM) series.[54] The [177Lu]Lu-CNC-V NPs were 
successfully radiolabeled with 177Lu (RCY = 64%) and loaded 
with vemurafenib (%LE = 19%) with a high radiochemical purity 
(RCP = 98.9%) upon the administration. The final concen-
trations of CNC NPs, vemurafenib, and 177Lu were 1  mg kg−1, 
2 mg kg−1, and 1.2 MBq per injection, respectively, formulated in 
150 µL of sterilized 1× PBS supplemented with 5% Solutol HS 
15. As expected, the [177Lu]Lu-CNC-V NPs demonstrated high but 
transient retention in the lung with average values of 47%ID g−1 
at 6 h, 37%ID g−1 at 24 h, and 18%ID g−1 at 72 h (Figure 8), 
which correspond to our previous report on the behavior of 
[111In]In-CNC NPs in vivo.[31] The transient accumulation is 
likely a result of the rheology of the needle-like particles in the 
Figure 7. Representative qualitative clonogenic cell survival assay in murine YUMM1.G1 and human A375 melanoma cells regrown after treatments 
in fresh medium (1), PLL-CNC NPs (2), free vemurafenib (3), free [177Lu]Lu3+ (4), [177Lu]Lu-CNC NPs (5), and [177Lu]Lu-CNC-V NPs (6) at doses 
of 1 MBq mL−1 for 177Lu, 40 µg mL−1 for CNC NPs, and 0.1 × 10−6 m for vemurafenib at 6, 24, and 48 h.
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lung vascular bed, as they tend to tumble close to the vessel 
walls and can potentially embolize in narrow capillaries and 
tumor neovascularization.[55,56] The entrapped [177Lu]Lu-CNC-V 
NPs in the blood vessels potentially sustain the release of vemu-
rafenib to the metastatic site by passive diffusion through the 
capillaries, meanwhile the ionizing β− particles emitted by 177Lu 
on the CNC NPs can penetrate and accumulate in metastatic 
lesions with a maximum penetration range of 2 mm in soft tis-
sues.[57] No acute adverse effects of this trapping were seen in 
the mice as the dispersion stability is properly maintained by the 
solubilizer in the optimized NP formulation. Major uptake was 
also seen in the liver (18–26%ID g−1) and spleen (28–60%ID g−1), 
which are sites for the clearance of nontargeted NPs through the 
mononuclear phagocyte system (MPS). The values in the kidney 
(<4%ID g−1) and other excised tissues (<1%ID g−1) revealed no 
significant accumulation over the period of studies indicating 
in vivo stability of the construct. Furthermore, there was no 
acute toxicity or severe side effects noticed during the course 
of the biodistribution studies. Therefore, the biodistribution 
profile and animal health status after the treatment suggest the 
potential use of the [177Lu]Lu-CNC-V NPs for treating melanoma 
metastases in the lung through the enhanced retention in the 
lung vascular bed and potentially in the metastasis neovascula-
ture itself.
The results of the ex vivo biodistribution were used to esti-
mate the absorbed dose in select organs, which could be 
used as a guideline for the safe administration dose of [177Lu]
Lu-CNC-V NPs in order to minimize the radiation burden in 
nontarget organs. The dosimetry calculation showed high total 
absorbed doses in the lung with tumor (232.38 cGy per MBq), 
liver (418.33 cGy per MBq), and spleen (1056.03 cGy per MBq) 
while only low absorbed doses were observed in the kidney 
(54.26  cGy per MBq), heart (36.42 cGy per MBq) and other 
tissues (<5  cGy per MBq, Table S5, Supporting Information). 
There is not much research to date on the dosimetry or radi-
otoxicity of 177Lu-radiolabeled nanoparticles in small animal 
models. However, widely varying doses ranging from 6 to 
55.5  MBq of 177Lu-radiolabeled peptides and antibodies have 
been used in therapeutic studies for mice,[58–61] which could 
be used as a starting point for the estimation of safe radioactive 
doses in the treatment plan. Naturally, the clearance patterns 
and rates for peptides and antibodies are considerably different 
from nanomaterials, and the role of the spleen as a dose-lim-
iting organ in this experimental setup cannot be overlooked.
2.8. Therapeutic Studies
Following the biodistribution study, therapeutic studies were 
conducted to explore the potential synergistic effects of vemu-
rafenib chemo- and 177Lu radiotherapy delivered by the thera-
nostic [177Lu]Lu-CNC-V NPs through monitoring of the survival 
rate of YUMM1.G1 lung metastatic melanoma-bearing animals 
comparing to the survival in animals treated with the vehicle 
only (negative control), free vemurafenib (positive control), 
and the [177Lu]Lu-CNC NPs alone. The [177Lu]Lu-CNC NPs were 
selected as the single-modality treatment where the therapeutic 
efficacy is solely generated from the ionizing radiation of 177Lu, 
as the biodistribution pattern of free [177Lu]Lu3+ would be con-
siderably different and studying the radiometal alone would not 
be meaningful in terms of tumor accumulation according to 
the results of the cell uptake assay in YUMM1.G1. After 14 d 
of tumor inoculation, the first treatment was administered fol-
lowed by the second round of treatment after 10 d. The animal 
weight and body condition score were monitored daily after 
the initiation of the treatment and lung with tumor tissues 
and vital organs (e.g., liver, kidney, and spleen) were collected 
to observe the tumor burden and potential metastasis in other 
organs at the humane endpoint (Figure 9A). The injected [177Lu]
Lu-CNC NPs and [177Lu]Lu-CNC-V NPs were prepared at high 
radiolabeling yield and radiochemical purity. The radiochemical 
yield, radiochemical purity, drug loading efficiency, and drug 
loading degree of the [177Lu]Lu-CNC NPs and [177Lu]Lu-CNC-V 
NPs for both constructs are compiled in Table S6, Supporting 
Figure 8. Ex vivo biodistribution profiles of the radioactivity after the administration of the [177Lu]Lu-CNC-V NPs in YUMM1.G1 lung metastatic mela-
noma-bearing C57BL/6NRj female mice at 6, 24, and 72 h postinjection. The values represent the mean ± s.d. (n = 3). %ID g−1 = percent of injected 
dose per gram of tissue, S.I. for the small intestine, and L.I. for the large intestine.
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Information. The administered doses of 177Lu, vemurafenib, and 
CNC NPs were fixed at 2 MBq, 3.5 mg kg−1, and 1.25 mg kg−1, 
respectively, per treatment round. The humane endpoints were 
set based on the weight loss exceeding the 20% threshold using 
the weight on the second treatment day as the baseline in com-
bination with the health status of the animals (body condition 
score of 2 on two consecutive observations, labored breathing, 
and cyanosis). The Kaplan–Meier survival analysis revealed 
superior therapeutic effects of the [177Lu]Lu-CNC-V NPs com-
pared to other groups (the Mantel-Cox test, p-value <  0.0001) 
after treatments (Figure  9B). The animals treated with the 
theranostic [177Lu]Lu-CNC-V NPs displayed the longest median 
survival time of 27 d after treatment followed by cohorts treated 
with the [177Lu]Lu-CNC NPs (17 days), free vemurafenib (13 d), 
and vehicle (12 d). There was no acute toxicity observed in any 
of the treatment groups upon administration. The survival 
studies demonstrated the evident synergism of vemurafenib 
chemotherapy and 177Lu radiotherapy generated from the [177Lu]
Lu-CNC-V NPs in pulmonary metastatic melanoma model, 
which pave the way for the development of CNC-based thera-
nostic nanosystem for combination therapy of metastatic mela-
noma with improved pharmacokinetics and antitumor efficacy.
Furthermore, the cohort treated with the [177Lu]Lu-CNC-V 
NPs showed less tumor burden in the lung at the humane 
endpoint compared to the other treatment groups (Figure 9C). 
Although the survival of mice treated with the [177Lu]Lu-CNC-V 
NPs was improved, it could not be further prolonged in this 
study because of ultimately fatal secondary metastases found in 
the cardiac muscle (75%, 6/8, Figure S4, Supporting Informa-
tion) and thoracic cavity (25%, 2/8). These were not discovered 
in other treatment groups, suggesting that they are not char-
acteristic of the progression of YUMM1.G1 tumors. Further 
studies into this are warranted, as this is to our knowledge the 
first account of the use of this cell line in an orthotopic model 
of lung metastatic melanoma. In general, cardiac metastasis is 
rarely found at the first instance in intravenous models, which 
is similar to the observations in this study. This might be a 
result of the escape of radiation- or vemurafenib-resistant cells 
from the original tumor site. There are four possible pathways 
to the spread of cells to the heart and chest cavity, including 
direct extension, the bloodstream, the lymphatic system, and 
intracavitary diffusion through the inferior vena cava or pulmo-
nary veins.[62] Among these, the lymphatic system is believed to 
be the most plausible route since the lung and heart have mul-
tiple connective lymph channels that resistant melanoma cells 
could migrate in, coalesce into the mediastinum and eventually 
drain to the thoracic duct.[63] Future efforts should be targeted 
to resolving this issue with the DDS, potentially by increasing 
the radioactive or pharmaceutical doses or adjusting the timing 
and frequency of the therapeutic administration which fell 
beyond the scope of this study. Also, studies with less aggres-
sive human BRAF V600E-positive A375 xenografts or patient-
derived xenografts are warranted.
Histological examination of the H&E sections of select vital 
organs after treatment with all formulations revealed normal 
architecture with no sign of radiation burden or secondary 
metastasis compared to the vehicle control group (Figure S5, 
Supporting Information). This indicated no severe radiotoxicity 
in liver and spleen tissues after two consecutive treatments and 
suggested safety of the theranostic formulation. However, the 
immunohistochemical Ki-67 staining of the lung infiltrated 
tumor at the humane endpoints showed no significant dif-
ference in cell proliferation markers in all treatment groups 
(Figure S5, Supporting Information). This is likely because the 
animals from each group were euthanized upon meeting the 
criteria for a humane endpoint, at a minimum of 12 d after the 
second treatment (vehicle group) or considerably later, not at 
a fixed time point after the treatment. As a consequence, dif-
ferences in the impact of the treatments on the proliferative 
capacity of the tumor cells could not be detected. These effects 
between the treatment groups could have been more evident 
closer to the time of theranostic nanosystem administration. 
Furthermore, in patients, BRAF kinase inhibition has been 
shown to elicit severe adverse effects if not discontinued during 
EBRT,[64] which were not seen in this study with local radio-
therapy. Therefore, it seems that the radiosensitizing effect of 
Figure 9. A) Timeline of therapeutic studies, B) Kaplan-Meier survival plot as a function of time after treatments with the vehicle (negative control), 
free vemurafenib, [177Lu]Lu-CNC NPs, and [177Lu]Lu-CNC-V NPs (n = 7–8 per group), where the administered doses of vemurafenib, CNC NPs, and 
radioactivity were fixed at 3.5, 1.25 mg kg−1, and 2 MBq per animal per treatment round, respectively. Day 0 on the x-axis indicates as the day of the 
second treatment. C) Representative images of tumor burden in the lung tissue collected at the humane endpoint of each injected formulation.
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vemurafenib could be harnessed to potentiate the effects of the 
radiotherapy in this previously unexplored strategy to the treat-
ment of pulmonary metastasis of melanoma.
In summary, the therapeutic study results confirm that the 
transient trapping of the theranostic CNC NP-based DDS in the 
lung is a viable strategy for therapeutic delivery to the lung and 
to pulmonary metastases, alluding to potential clinical utility 
of CNC-based DDS after systemic administration, which has 
remained challenging with CNC-based biomaterials to date.
3. Conclusion
Taken together, the [177Lu]Lu-CNC-V NPs developed in this work 
demonstrate the feasibility of using CNC NPs as a naturally 
sourced and renewable nanoscale platform for theranostic nano-
systems for the treatment of BRAF V600E positive metastatic 
melanoma in the lung with radiotherapy and kinase inhibition 
after systemic delivery. The energy and tissue range of β− parti-
cles emitted by 177Lu as well as the rate of the sustained release of 
the vemurafenib were appropriate for the application, resulting 
in the prolonged survival of YUMM1.G1 tumor-bearing mice 
receiving the theranostic combination. The system is modular, 
as the trivalent radiometal, the capping agent, and drug payload 
can be exchanged to generate new theranostic combinations and 
tailor the properties of the DDS. Furthermore, future efforts 
should be dedicated to elucidating the mechanism of the tran-
sient trapping of the CNC NPs in the lung and the possibility 
of modulating this behavior through CNC NP engineering to 
enhance delivery to lung tissue and pulmonary metastases.
4. Experimental Section
Materials and Chemicals: All general chemicals and anhydrous 
organic solvents as well as human serum were purchased from Merck 
(St. Louis, MO, USA) unless otherwise denoted and used without 
additional purification. Cotton fiber derived CNC NPs were prepared 
from ashless Whatman filter paper through acid hydrolysis as described 
in literature[65,66] and the acid residue was washed out with excess 
amount of dimethyl sulfoxide (DMSO) and ultrapure water before 
further syntheses. The 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic 
acid)-10-(4-aminobutyl) acetamide (DOTA-amine or DOTA-NH2) was 
acquired from Macrocyclics (Plano, TX, U.S.A.). Vemurafenib (purity 
>  98%) was obtained from Adooq Bioscience (Irvine, CA, USA). Poly-
l-lysine hydrochloride or PLL (MW 1.6  kDa with 10 repeating units of 
l-lysine) was purchased from Alamanda Polymers (Huntsville, AL, 
USA). The dialysis membrane (MWCO 12–14  kDa) was obtained from 
Spectrum Laboratories (Waltham, MA, USA). [177Lu]LuCl3 was acquired 
from Curium Pharma (Petten, The Netherlands). The polypropylene 
protein LoBind microcentrifuge tubes (1.5  mL) were obtained from 
Eppendorf (Hamburg, Germany). The Solutol HS 15 solubilizer was 
acquired from BASF ChemTrade GmbH (Burgbernheim, Germany). 
The glass microfiber chromatography sheets impregnated with silicic 
acid (iTLC-SA) were acquired from Agilent Technologies (Folsom, CA, 
USA). Donor human plasma (FFP 24) was obtained from the Finnish 
Red Cross Blood Service (Helsinki, Finland) under an ethical approval 
for research purposes. Ultrapure water (18.2 MΩ cm at 25  °C, 2 ppb 
TOC) was prepared in-house by a Milli-Q Integral 10 water purification 
unit equipped with 0.22 µm Millipak Express 40 membrane filter (Merck 
Millipore, Burlington, MA, USA) at the point of dispense for producing 
bacteria- and particulate-free ultrapure water. Cell culture reagents and 
general procedures are described in the Supporting Information.
Preparation of DOTA-Modified CNC NPs: The bifunctional DOTA 
chelator-functionalized CNC (DOTA-CNC) NPs used in this work were 
synthesized by the conjugation of DOTA-amine to the hydroxyl groups 
on the surface of the CNC NPs as previously reported.[31] Briefly, the 
CNC NPs were dispersed in anhydrous DMSO at a concentration of 
5  mg mL−1 and sonicated for 5  min at 20% amplitude tip sonicator 
(QSonica, Newton, CT, USA). Carbonyldiimidazole (CDI, 2 eq w/w) 
in anhydrous DMSO was added to the CNC solution while flushing 
with argon flow and constant agitation. The reaction was left stirring 
overnight in a temperature-controlled silicone oil bath at 60  °C under 
argon atmosphere. The unreacted CDI was washed out twice with 
5 mL of fresh DMSO and the CDI-activated CNC NPs were collected by 
centrifugation at 4000 rpm for 5 min (Heraeus Megafuge 1.0R, Thermo 
Fisher Scientific, Waltham, MA, USA). The CDI-activated CNC NPs 
were redispersed in anhydrous DMSO (5  mg mL−1) and the solution 
was constantly flushed with argon flow for 10 min while stirring. Then, 
the DOTA-amine (1 eq w/w) in anhydrous DMSO was added dropwise 
to the CDI-activated CNC solution. The reaction was continued for 3 d 
under argon atmosphere at 60  °C, meanwhile, the argon balloon was 
refilled daily to maintain a sufficient inert atmosphere inside the reaction 
flask. Following the 3-day reaction, the mixture was centrifuged and 
the collected DOTA-CNC NPs were washed twice with 5  mL of fresh 
DMSO to remove any unreacted DOTA-amine. The DOTA-CNC NPs 
were further dialyzed against ultrapure water for 3 d with at least four 
changes of water daily. Finally, the DOTA-CNC NPs were collected by 
centrifugation and lyophilized.
Material Characterization: The elemental composition of unmodified 
and modified CNC NPs was analyzed using a Vario MICRO Cube 
CHNS analyzer (Elementar Analysensysteme GmbH, Lagenselbold, 
Germany) and are reported as a percent of carbon (C), hydrogen (H), 
and nitrogen (N). The CNC NPs were further characterized with a 
Spectrum One Fourier transform infrared spectrometer (FTIR) equipped 
with an attenuated total reflectance (ATR) unit (PerkinElmer Instruments 
LLC, Shelton, CT, USA). The electrokinetic potential of unmodified and 
modified CNC NPs in ultrapure water (ζ-potential) was measured using 
a Zetasizer Nano ZS instrument (Malvern, Worcestershire, UK) at a 
concentration of 300 µg mL−1. The morphology and dimensions (width 
and length) of CNC NPs were determined with a Hitachi S-4800 field 
emission-scanning electron microscope at 10  kV (FE-SEM, Hitachi, 
Tokyo, Japan). The FE-SEM samples were prepared by dispersing the 
CNC NPs in ultrapure water at a concentration of 25  µg mL−1 and 
sonicated for 2  min. The silicon wafer substrates were taped to the 
cylindrical specimen holder and wiped with ultrapure water followed by 
blowing with the compressed air to remove dust from the surface. Then, 
an aliquot of CNC samples (10 µL) was applied on the silicon wafer and 
left to dry in a desiccator overnight. The same procedure was repeated 
once on each substrate in order to get an adequate number of particles 
for the imaging. Prior to imaging, the samples were coated with a 3 nm 
layer of Au–Pd alloy in a high-resolution sputtering coater (208HR, 
Cressington Scientific Instruments, Watford, UK) in order to increase the 
conductivity and signal-to-noise ratio of the samples. The dimensions 
(width and length) of each sample (n ≥ 100 particles) were determined 
from the images using ImageJ 1.52i software.
Radiolabeling of DOTA-CNC NPs: Before radiolabeling experiments, 
ultrapure water used for the preparation of all radiolabeling buffer 
solutions was pretreated with Chelex 100 ion-exchange resin (Bio-Rad, 
Hercules, CA, USA) at a concentration of 5  g L−1 for 24 h and filtered 
through a 0.22  µm membrane to obtain the metal-free water. The 
DOTA-CNC NPs (1  mg mL−1) were dispersed in 0.2 m ammonium 
acetate buffer (pH 4.0) in a 1.5 mL Protein LoBind microcentrifuge 
tube (Eppendorf, Hamburg, Germany). The DOTA–CNC solution was 
sonicated for 5  min at 20% amplitude on a tip sonicator. [177Lu]LuCl3 
(20–180 MBq) was added to the DOTA–CNC solution. The radiolabeling 
reaction was heated to 100  °C in a digital dry bath heater (AccuBlock, 
Labnet International, Edison, NJ, USA) placed on an orbital shaker at 
600  rpm for 1 h. Following the incubation, the reaction mixture was 
equilibrated to room temperature and quenched with 100  µL of 50  × 
10−3 m DTPA solution. The reaction vial was centrifuged at 10 000 g for 
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5 min to collect the [177Lu]Lu-CNC pellet. The supernatant was removed, 
and the product pellet was purified with sequential washes in 50  × 
10−3 m DTPA solution twice, three times with 1× PBS (pH 7.4), and once 
with metal-free ultrapure water with a collection of the radiolabeled 
CNC NPs by centrifugation after each step. The radioactivity in both 
supernatant and the collected pellet was monitored using a VDC-603 
dose calibrator (VIK-202 ionization chamber model, Comecer, Joure, The 
Netherlands) after every step. Then, the purified radiolabeled product 
was redispersed in 1× PBS (pH 7.4) and the quality control was done 
by radio-TLC. An aliquot of radiolabeled CNC solution (1–2  µL) was 
spotted on the iTLC-SA chromatography sheet and run in a closed 
glass chamber with 0.1 m citrate buffer (pH 5.0). The [177Lu]Lu-CNC 
NPs remain at the baseline of the application spot (Rf  = 0) while the 
free [177Lu]Lu3+ moves along with the solvent front (Rf = 0.9–1.0). After 
air-drying, the iTLC-SA sheet was exposed to a digital imaging plate 
for photostimulated luminescence (PSL) detection (Fuji BAS-TR2025, 
20 × 25  cm) for 2  min. The imaging plate was scanned on a Fujifilm 
Fluorescent Image Analyzer (FLA-5100  V.1, Fuji Film Photo, Tokyo, 
Japan). The radiochemical purity (RCP) of the [177Lu]Lu-CNC NPs was 
analyzed using AIDA image analysis software version 5.0 SP 3 (Elysia-
Raytest GmbH, Straubenhardt, Germany).
Radiolabel Stability and EDTA/Fe3+ Challenges: The in vitro radiolabel 
stability of the [177Lu]Lu-CNC NPs was evaluated in simulated 
physiological conditions, including 1× PBS (pH 7.4), and 50 and 100% 
human plasma, and in the presence of competing for 0.2 × 10−3 m FeCl3 
and 2  × 10−3 m EDTA. The [177Lu]Lu-CNC NPs were dispersed in the 
specified buffer at a concentration of 100 µg mL−1 and incubated at 37 °C 
at 500  rpm. Samples (2  µL) were drawn and spotted on the iTLC-SA 
chromatography paper at specified time points (1, 2, 4, 6, 16, 24, 48, 72, 
and 96 h). The radio-TLC chromatograms were run in 0.1 m citrate buffer 
(pH 5.0) and the percentage of 177Lu remaining on the surface of the 
CNC NPs was quantified using digital autoradiography as described in 
the previous section. All assays were carried out in triplicate.
Drug Loading: The drug loading of both nonradiolabeled and 
radiolabeled CNC NPs was carried out in a one-pot reaction. Either 
unmodified CNC NPs or [177Lu]Lu–CNC NPs (1  mg) were dispersed in 
200 µL of anhydrous DMSO in a 1.5 mL Protein LoBind microcentrifuge 
tube. Vemurafenib (1:1 w/w) and PLL (1:10 w/w) in anhydrous DMSO 
were added to the CNC dispersion. The reaction volume was adjusted 
with fresh anhydrous DMSO to a total solid concentration of 6 mg mL−1. 
The reaction mixture was sonicated for 2  min at 30% amplitude and 
further incubated at 37  °C for 1 h on a shaker at 750  rpm (Eppendorf 
Thermomixer C, Eppendorf, Hamburg, Germany). The reaction vial 
was centrifuged at 10 000  g for 10  min. The supernatant was removed 
and filtered through a 0.2  µm PVDF 13 mm diameter filter (Acrodisc, 
Pall Corporation, Port Washington, NY, USA). The amount of 
vemurafenib in the supernatant (unbound drug) was quantified using 
high-performance liquid chromatography (Prominence HPLC system, 
Shimadzu Corporation, Kyoto, Japan). The separations were carried out 
on a reverse-phase XBridge C18 analytical column (130 Å, 5  µm, 4.6 × 
250 mm, Waters Corporation, Milford, MA, USA) with an isocratic flow 
of 0.1 m glycine buffer (pH 9.0) and acetonitrile (45:55) eluent system 
at a flow rate of 0.9 mL min−1, and 254 nm UV detection. The retention 
time of vemurafenib was 8.70–8.79  min. The amount of vemurafenib 
was quantified using a vemurafenib standard curve ranging from 
1.56 to 200  µg mL−1 (R2  = 1). The drug loading efficiency (%LE) and 
loading degree (%LD) were determined using equations detailed in the 
Supporting Information. All samples were analyzed in triplicate.
In Vitro Drug Release Profiles: The in vitro drug release experiments 
were conducted in 1× PBS buffer (pH 7.4) and tumor microenvironment 
mimicking conditions (10  × 10−3 m acetate buffer pH 5.5, representing 
the late endosome).[67] Both buffer systems were supplemented with 10% 
(v/v) human serum to induce sink conditions for drug dissolution. The 
nonradiolabeled PLL-CNC-V NPs and [177Lu]Lu-CNC-V NPs containing 
200 µg of CNC NPs and 22 µg of vemurafenib were dispersed in 500 µL 
of the respective buffers in Protein LoBind microcentrifuge tubes and 
incubated at 37 °C with 500  rpm shaking. At each time point (1, 2, 4, 
6, 12, 24, 48, 72, and 96 h), sample vials were centrifuged at 5000 rpm 
for 10 min and the supernatant was collected to a new microcentrifuge 
tube. The sample pellets were redispersed with an equal initial volume 
(500  µL) of corresponding media and the incubation was continued. 
Proteins in the isolated supernatant were denatured by adding an ice-
cold acetonitrile (1:1 v/v) and pelleted by centrifugation at 9 000  g for 
10  min. The protein precipitates were discarded, and the collected 
supernatants were lyophilized overnight. The lyophilized samples were 
dissolved in 500 µL of HPLC grade DMSO and passed through 0.2 µm 
PVDF filter before HPLC analysis. The amount of released vemurafenib 
was quantified using the HPLC method described previously. All samples 
were analyzed in triplicate.
In Vitro Cell Viability Studies: The in vitro cytotoxicity was determined 
using a commercial CellTiter-Glo luminescent cell viability assay, which 
is the most appropriate assay for the CNC NPs according to previous 
reports.[31,32] Murine YUMM1.G1 and human A375 cell lines were chosen 
as mouse and human melanoma cell models harboring the activating 
BRAF V600E mutation while murine B16-F10 skin melanoma cell 
expressing wild-type BRAF gene was used as the negative control cell 
line. Cells were plated at a density of 5000 cells per well on an opaque-
walled 96-well plate with clear bottom in 100  µL of the corresponding 
media and allowed to attach overnight. The media was removed 
and replaced with 100  µL of the corresponding media containing free 
vemurafenib, PLL-CNC NPs (empty particle), or PLL-CNC-V NPs at drug 
concentration of 0.1 × 10−6, 0.5 × 10−6, 1.0 × 10−6, and 1.5 × 10−6 m. The 
PLL-CNC NP concentrations were determined in correspond with the 
amount of the CNC NPs used in the PLL-CNC-V formulation: 0.5, 2.2, 
4.5, and 6.7 µg mL−1 for 0.1 × 10−6, 0.5 × 10−6, 1.0 × 10−6, and 1.5 × 10−6 m, 
respectively. Fresh medium and Triton X-100 solution (1% v/v) were used 
as negative and positive controls for cytotoxicity, respectively. The plates 
were incubated at 37 °C, 5% CO2 atmosphere and 95% relative humidity 
for 6, 24, 48, and 72 h. Moreover, to corroborate the sensitivity of the cell 
lines to vemurafenib, western blot analysis was carried out to observe the 
decrease in phosphorylation of mitogen-activated protein kinase kinase 
(MEK, the downstream target of BRAF) in response to vemurafenib at 
0.1 × 10−6 and 1 × 10−6 m concentration for 6, 24, and 48 h. The protocols 
for cytotoxicity determination and western blot analysis are detailed in 
the Supporting Information.
Cellular Uptake Studies of Radiolabeled CNC Constructs: The in vitro 
cell internalization of radiolabeled CNC constructs was studied in 
YUMM1.G1 and A375 melanoma cell lines. Cells were seeded on a 
transparent 12-well plate at a density of 25 000 cells per well and allowed 
to attach overnight. Prior to the experiments, the cells were acclimatized 
to the CO2 independent medium supplemented with 10% FBS and 1% 
penicillin–streptomycin at 37  °C incubator with 0% CO2 for at least 
30  min. The medium was removed and replaced with 1  mL of CO2 
independent medium containing free [177Lu]LuCl3+, [177Lu]Lu-CNC NPs, 
or [177Lu]Lu-CNC-V NPs. The radioactivity of 177Lu in each sample was set 
at 1 MBq mL−1 while the CNC NPs and vemurafenib doses were 40 µg 
mL−1 and 0.1 × 10−6 m, respectively. Cells were incubated at 37 °C for 1, 6, 
24, and 48 h. At each time point, the cells were treated to yield fractions 
for unbound, membrane-bound and internalized radioactivity. Details for 
the uptake protocol are described in the Supporting Information.
Clonogenic Assay: The in vitro clonogenic cell survival was evaluated in 
murine YUMM1.G1 and human A375 melanoma cell lines. Both cell lines 
were treated with non-radiolabeled PLL-CNC NPs, free vemurafenib, free 
[177Lu]LuCl3+, [177Lu]Lu-CNC NPs, and [177Lu]Lu-CNC-V NPs while the 
untreated cells (negative control for cytotoxicity) were incubated with 
CO2 independent medium throughout the study. The concentrations 
of radioactivity, CNC NPs, and vemurafenib were fixed at 1 MBq mL−1, 
40 µg mL−1, and 0.1 × 10−6 m, respectively. At the specified time points 
(6, 24, and 48 h), the cells were collected and cultured for further 10 d 
in fresh medium on six-well plates. At the end of the assay period, the 
cell colonies were stained with crystal violet and the plates were scanned 
for colony observation. The experimental procedure is described in the 
Supporting Information.
Ex Vivo Biodistribution, Dosimetry, and Therapeutic Studies: All animal 
experiments in this work were conducted under a project license number 
ESAVI/12132/04.10.07/2017 approved by the National Board of Animal 
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Experimentation in Finland and in compliance with the European 
Union Directive 2010/63/EU. In general, animals were group-housed 
in conventional polysulfones cages supplied with aspen bedding, 
nesting material (Tapvei, Harjumaa, Estonia) and enrichment (aspen 
blocks and disposable cardboard hut). Pelleted food (Teklad 2019C diet, 
Envigo, Huntingdon, UK) and tap water were provided ad libitum. The 
environmental conditions of the animal housing unit were maintained 
at 12:12 h light/dark cycle, 22 ± 1  °C, and 55 ± 15%  relative humidity 
throughout the experimental period. Both ex vivo biodistribution and 
therapeutic studies were carried out in YUMM1.G1 lung metastatic 
melanoma-bearing C57BL/6NRj mice (female, weighing 16–19  g, aged 
8–12 weeks, Janvier Laboratories, Le Genest-Saint-Isle, France). For 
the orthotopic model of YUMM1.G1 metastatic melanoma in the lung, 
1 × 106 YUMM1.G1 cells (viability >  95%) in 150 µL sterilized 1× HBSS 
were intravenously injected via the lateral tail vein to conscious mice. 
The tumors were allowed to develop for at least 14 d before the start 
of the nanotheranostic studies. The summary of injected doses of 
nanosystem components for biodistribution and therapeutic studies is 
compiled in Table S7 (Supporting Information).
For ex vivo biodistribution, the [177Lu]Lu-CNC-V NPs were 
intravenously injected via the tail vein at a dose of 1.2 MBq of 177Lu, 
1  mg kg−1 of CNC NPs, and 2  mg kg−1 of vemurafenib in 150  µL of 
sterilized 1× PBS (pH 7.4) supplemented with 5% (v/v) Solutol HS 15. At 
predetermined time points (6, 24, and 72 h), mice were sacrificed by CO2 
asphyxiation followed by cervical dislocation to harvest interest tissue 
samples, including blood, pancreas, spleen, stomach, liver, kidney, lung 
with tumor, heart, small intestine, large intestine, skeletal muscle, tibia, 
occipital bone, and brain. The tissue samples were individually collected 
and weighted in the 5 mL liquid scintillation tubes. The radioactivity in 
tissue samples was counted using an automatic gamma counter 1480 
Wizard 3″. The results were expressed as a percent of injected dose per 
weight of tissue (%ID g−1). The number of animals was set at n = 3 per 
each time point.
Following the ex vivo biodistribution study, the average activity 
concentration of 2–3 tissue specimens from each time point was 
fitted to a biexponential function to create a time-activity curve (TAC). 
For most tissues, the best TAC fit is composed of a one- or two-
phase exponential decay model. Notably, the spleen exhibited marked 
uptake over the measured time course, therefore, a trapezoidal model 
was used for this tissue up to the latest time point, after which it was 
assumed that clearance was determined entirely by radioactive decay. 
The cumulative uptake was calculated from the area under the uptake 
curves. The absorbed dose to all organs was estimated based on the 
assumption that the absorbed fraction is equal to 1 for β− emission of 
177Lu and 0 for the penetrating photon emission with the equilibrium 
absorbed dose constant of 0.085g·Gy/MBq·h (0.31 g·cGy/µCi·h). The 
estimated absorbed dose (cGy/MBq) in an individual organ was used 
as a guideline for the administration plan of safe and effective radiation 
dose in therapeutic studies to minimize the radiation burden in healthy 
tissues after the nanotheranostic construct administration.
In therapeutic studies, the animals were randomized into four groups 
after 14 d of the YUMM1.G1 tumor inoculation: vehicle (1× PBS with 6% 
Solutol HS 15), free vemurafenib (3.5 mg kg−1), [177Lu]Lu-CNC NPs, and 
[177Lu]Lu-CNC-V NPs (n = 7–8 per group). The [177Lu]Lu-CNC and [177Lu]
Lu-CNC-V groups were treated with the corresponding theranostic CNC 
formulations containing 2 MBq of 177Lu, 1.25 mg kg−1 of CNC NPs, and 
3.5 mg kg−1 of vemurafenib per treatment cycle. The second treatment 
for all groups was done 10 d after the first treatment. The animal 
weight and condition using body condition scoring[68] were monitored 
and recorded daily until the humane endpoint. At the endpoint, the 
lung tissue with the tumor and select vital organs (liver, spleen, and 
kidney) were collected in 10% (v/v) neutral buffered formalin and sent 
to histological analysis with hematoxylin and eosin (H&E) staining and 
immunohistochemistry for proliferation using the Ki-67 marker. Details 
for the immunohistochemical procedure are given in the Supporting 
Information.
Statistical Analysis: Quantitative data are presented as mean ± s.d. 
(n ≥ 3). A direct comparison between sample groups was made using 
unpaired Student’s t-tests where the statistical significance (p-value) was 
set at *p < 0.05, **p < 0.01, and ***p < 0.001. The survival in therapeutic 
studies was determined using Kaplan-Meier survival analysis with 
GraphPad Prism software version 8.0.1 (San Diego, CA, USA).
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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